Melbourne-based biotechnology firm CNSDose is gearing up for a commercial launch in the US of its genetically powered clinical decision support tool for antidepressant dosing, with plans for a global roll-out, including in Australia, next year.

The tool involves a genetic test for two biomarkers for how readily medications can reach the brain and a subsequent report guiding prescribers on the probable efficacy of 20 commonly prescribed antidepressants.